Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical research study is to evaluate the safety and effectiveness (good
and bad effects) of a combination of three different drugs, pomalidomide, pegylated liposomal
doxorubicin, and dexamethasone when used to treat relapsed (the disease came back) or
refractory (the disease did not respond to past treatment) multiple myeloma. Different
dosages (amount of study drug) of pomalidomide are first being tested to determine if there
are any side effects or risks associated with combining this study drug with the other two
listed. Once the optimal dose is decided on, the study will change its focus to determining
the effectiveness of the study drug in this combination.